BPC-157 & TB-500 Blend: The Recovery Standard

The Onyx Biolabs BPC-157 & TB-500 Blend is a specialized research formulation that combines two of the most potent regenerative peptides into a single, synergistic ratio. This blend is widely regarded in the scientific community as the “Gold Standard” for researching soft tissue repair and musculoskeletal recovery.

By combining BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4), this protocol targets two distinct but complementary pathways of healing: angiogenesis (blood vessel formation) and cellular migration.

The Synergy of the Blend Research suggests that studying this BPC-157 & TB-500 Blend yields superior results compared to isolating the compounds, due to their dual-action mechanism:

• BPC-157 (The Healer): Primary research focuses on its ability to upregulate growth hormone receptors in tendon fibroblasts and accelerate angiogenesis. It is the “fuel” that ensures damaged tissues receive the blood flow and nutrients needed for repair.
• TB-500 (The Mover): Functions by sequestering actin, a protein essential for cell structure and movement. This allows cells to migrate rapidly to the site of injury to begin the rebuilding process.
• Combined Effect: Together, they are hypothesized to accelerate the repair of tendons, ligaments, and muscle fibers while simultaneously reducing inflammation.

Research Applications & Storage This premium blend is supplied as a lyophilized powder to maintain stability. For research purposes, it must be reconstituted with Bacteriostatic Water. Once reconstituted, the solution is sensitive to temperature and must be stored at 2-8°C.

References

1. Chang H, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology. 2011.

2. Goldstein AL, et al. Thymosin beta 4: actin-sequestering protein functions in cell migration and wound repair. Annals of the New York Academy of Sciences. 2007.

3. Trezza M, et al. Peptide BPC 157 and its potential in soft tissue healing. Molecules. 2021.